• Triglyceride Form of Omega-3
• Over 1200 milligrams of EPA & DHA Omega-3s in a Single Teaspoon
• Product of Norway
• Lemon Flavored with No Fishy Oil Aftertaste

Res-Q 1250 Liquid is a concentrated triglyceride form of omega-3 containing more EPA and DHA omega-3 in a single spoonful than most other supplements. Omega-3s, sometimes called fatty acids, are "good fats" and an important nutrient often lacking in many American diets.

Res-Q 1250 Liquid is ultra-purified to give you omega-3s with no fish oil aftertaste. Convenient and delicious light lemon flavor. A nice alternative to capsules.  Designed for people of all ages.*

8 REASONS TO TAKE FISH OIL

The omega-3s in fish oil are found to support: 

1. A healthy heart*
2. Triglycerides*
3. Circulation*
4. The natural inflammatory response*
5. Joint mobility and flexibility*
6. Brain and eye health*
7. Overall health and wellbeing*
8. Mood*

CONCENTRATED OMEGA-3s

Res-Q 1250 Liquid is formulated to contain approximately 1,250 mg of combined EPA (eicosapentaenoic acid) and DHA (docosahexeanoic acid), the two most researched omega-3s.

Growing evidence shows that EPA and DHA are anti-inflammatory and heart healthy.*

• Why You Need EPA: EPA supports a balanced inflammatory response throughout the body and promotes cardiovascular funtion.* Recent research indicates that chronic inflammation is considered to be a major trigger for disease.

• Why You Need DHA: DHA is the most abundant omega-3 in the brain and retina.  Cells in your body use it to communicate with each other. DHA is important to brain development and function.*

• How much EPA and DHA in Each Res-Q 1250 Spoonful?  You receive 740-825 mg of EPA and 460-550 mg of DHA in each spoonful. That is approximately 1250 mg of purified omega-3s; three to four times more than other brands.

CLEAN AND PURIFIED IN NORWAY

The Res-Q 1250 Liquid undergoes an extensive purification process to ensure its purity and safety.* We start with small cold-water fish caught in deep regions of the ocean.

In a pharmaceutical licensed, Good Manufacturing Practices (GMP) certified facility in the fjords of Norway, the fish oil undergoes an extensive purification process including molecular distillation to ensure it is clean and free of PCBs, dioxins and heavy metals like mercury. Each batch is independently three-party tested for purity from 250 possible toxic compounds by Eurofins, one of the top toxicology labs in the world. Lastly Res-Q 1250 is bottled in the U.S.A.

STAYS FRESH WITH NO FISH OIL AFTERTASTE

We bottle the liquid in a dark brown glass container and add a special antioxidant blend to maintain freshness. To keep it tasting fresh and delicious a very light lemon/lime flavor is added for a pleasant taste.   

SATISFACTION MONEY-BACK GUARANTEE

If you are not completely satisfied with Res-Q 1250 Omega-3 Fish Oil Liquid simply return it within 60 days of purchase and we will refund your product purchase.  

*These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure or prevent any disease. It is recommended that a physician be consulted before taking any supplements. Results not typical and may vary.

Research

1. Berger et al. “Metabolic and nutritional support in acute cardiac failure.” Curr Opin Clin Nutr Metab Care. 2003 Mar; 6(2):195-201
2. Nair SS, et al. “Prevention of cardiac arrhythmia by dietary (n-3) polyunsaturated fatty acids and their mechanism of action.” J Nutr. 1997 Mar;127(3):383-93
3. De Caterina R. et al. “Antiarrhythmic effects of omega-3 fatty acids: from epidemiology to bedside.”. Am Heart J. 2003 Sep;146(3):420-30
4. Bucher HC, et al. “N-3 polyunsaturated fatty acids in coronary heart disease: a meta-analysis of randomized controlled trials.” Am J Med. 2002;112:298-304
5. Supari F., et al. “Fish oil treatment decreases superoxide anions in the myocardium and coronary arteries of atherosclerotic monkeys.” Circulation. 1995 Feb 15;91(4):1123-8
6. Richter WO., et al. “Long-chain omega-3 fatty acids from fish reduce sudden cardiac death in patients with coronary heart disease.” Eur J Med Res. 2003 Aug 20;8(8):332-6
7. Yli-Jama P. “Serum-free fatty acid pattern and risk of myocardial infarction: a case-control study.” J Intern Med. 2002 Jan;251(1):19-28
8. Mozaffarian D, et al. “Effect of Fish Oil on Heart Rate in Humans…” Circulation. 2005 Sep 19 [Epub ahead of print]
9. Paillard F. “Nutritional counseling for coronary and hypertensive patients.” Arch Mal Coeur Vaiss. 2003 Sep;96:27-33
10. Armitage JA. “Increased blood pressure later in life may be associated with perinatal n-3 fatty acid deficiency.” Lipids. 2003 Apr;38(4):459-64
11. Mori TA. et al. “Docosahexaenoic acid but not eicosapentaenoic acid lowers ambulatory blood pressure and heart rate in humans.” Hypertension. 1999;34:253-260
12. Frenoux JM. et al. “A polyunsaturated fatty acid diet lowers blood pressure and improves antioxidant status in spontaneously hypertensive rats.” J Nutr. 2001 Jan;131(1):39-45
13. Rousseau et al. “Dietary n-3 polyunsaturated fatty acids affect the development of renovascular hypertension in rats.”. Mol Cell Biochem. 2001 Sep;225(1-):109-19
14. Morris MCB. “Does fish oil lower blood pressure? A meta-analysis of controlled trials.” Circulation 1993
15. Curtis CL. “Effects of n-3 fatty acids on cartilage metabolism.” Proc Nutr Soc. 2002 Aug;61(3):381-9
16. James MJ et al. “Dietary omega-3 fats as adjunctive therapy in a prototypic inflammatory disease: issues and obstacles for use in rheumatoid arthritis.” Prostaglandins Leukot Essent Fatty Acids. 2003 Jun;68(6):399-405
17. Simopoulos AP. “Omega-3 fatty acids in inflammation and autoimmune diseases.” J Am Coll Nutr. 2002 Dec;21(6):495-505
18. Cleland LG. “The role of fish oils in the treatment of rheumatoid arthritis.” Drugs. 2003;63(9):845-53
19. Durrington PN, et al. “An omega-3 polyunsaturated fatty acid concentrate administered for one year decreased triglycerides in simvastatin treated patients with coronary heart disease and persisting hypertriglyceridaemia.” Heart. 2001;85:544–548
20. “The effect of a diet enriched with omega-3 polyunsaturated fatty acids on the indices of the blood fibrinolytic system in patients in the initial stages of ischemic heart disease.” Kardiologiia. 1993;33(6):21-5
21. Saynor R. et al. “The long-term effect of dietary supplementation with fish lipid concentrate on serum lipids, bleeding time, platelets, and angina.” Atherosclerosis. 1984 Jan;50(1):3-10
22. Menendez JA. “Overexpression and hyperactivity of breast cancer associated fatty acid synthase (oncogenic antigen-519) is insensitive to normal arachidonic fatty acid-induced suppression in lipogenic tissues, but it is selectively inhibited by tumoricidal alpha-linolenic and gammalinolenic fatty acids…” Int J Oncol. 2004 Jun;24.)
23. Nkondjock A. “Intake of specific carotenoids and essential fatty acids and breast cancer risk in Montreal, Canada.” Am J Clin Nutr. 2004 May;79
24. Jordan A. “Effect of an omega-3 fatty acid containing lipid emulsion alone and in combination with 5-fluorouracil (5-FU) on growth of the colon cancer cell line Caco-2.” Eur J Nutr. 2003 Dec;42(6):324-31
25. Hardman WE, et al. “Consumption of an omega-3 fatty acids product, INCELL AAFA, reduced side-effects of CPT-11 (irinotecan) in mice.” Br J Cancer. 2002;86:983-988
26. Holness MJ. “Acute omega-3 fatty acid enrichment selectively reverses high-saturated fat feeding-induced insulin hypersecretion but does not improve peripheral insulin resistance.” Diabetes. 2004 Feb;53 Suppl 1
27. Simoncikova P. “Comparison of the extrapancreatic action of gammalinolenic acid and n-3 PUFAs in the high fat diet-induced insulin resistance [corrected].” Endocr Regul. 2002 Nov;36 28. Shimura T. “Docosahexanoic acid (DHA) improved glucose and lipid metabolism in KK-Ay mice with genetic non-insulin-dependent diabetes mellitus (NIDDM).” Biol Pharm Bull. 1997 May;20
28. Holness MJ. “Diabetogenic impact of long-chain omega-3 fatty acids on pancreatic beta-cell function and the regulation of endogenous glucose production.” Endocrinology. 2003 Sep;1
29. “Resistance to Leptin Contributes to Obesity.” The Rockefeller University. 1997, Aug. 5
30. Kruger MC, et al. “Calcium, gamma-linolenic acid and eicosapentaenoic acid supplementation in senile osteoporosis.” Aging (Milano).1998;10:385–394
31. Albertazzi P, et al. “Polyunsaturated fatty acids. Is there a role in postmenopausal osteoporosis prevention?” Maturitas. 2002 May 20;42(1):13-22
32. Terano T. “Effect of omega 3 polyunsaturated fatty acid ingestion on bone metabolism and osteoporosis.” World Rev Nutr Diet. 2001;88:141-7
33. Högström, M et al. “n–3 Fatty acids are positively associated with peak bone mineral density and bone accrual in healthy men: the NO2 Study.” Am J Clin Nutr. 2007 85: 803-807
34. Morris MC. “Consumption of fish and n-3 fatty acids and risk of incident Alzheimer disease.” Arch Neurol. 2003 Jul;60
35. Hashimoto M. “Docosahexaenoic acid provides protection from impairment of learning ability in Alzheimer’s disease model rats.” J Neurochem. 2002 Jun;81
36. Farooqu AA. “Plasmalogens, phospholipase A2, and docosahexaenoic acid turnover in brain tissue.” J Mol Neurosci. 2001 Apr-Jun;16.
37. Malcolm Peet. “Essential fatty acids theoretical aspects and treatment implications for schizophrenia and depression.” Advances in Psychiatric Treatment 2002; 8 223-229
38. Murck H. “Ethyl-eicosapentaenoate and dexamethasone resistance in therapy-refractory depression.” Int J Neuropsychopharmacol. 2004 Jun;:1-9
39. Nemets B, et al. “Addition of Omega-3 Fatty Acid to Maintenance Medication Treatment for Recurrent Unipolar Depressive Disorder.” American Journal of Psychiatry 2002;159 477-479
40. Tsekos E. “Perioperative administration of parenteral fish oil supplements in a routine clinical setting improves patient outcome after major abdominal surgery.” Clin Nutr. 2004 Jun;23
41. Switzer KC. (n-3) Polyunsaturated fatty acids promote activation-induced cell death in murine T lymphocytes.” J Nutr. 2003 Feb;133
42. Walton AJE, et al. “Dietary fish oil and the severity of symptoms in patients with systemic lupus erythematosus.” Ann Rheum Dis. 1991;50:463–466
43. Cho E, et al. “Prospective study of dietary fat and the risk of age-related macular degeneration.” Am J Clin Nutr. 2001 Feb;73(2):209-18
44. Seddon JM, et al. “Dietary fat and risk for advanced age-related macular degeneration.” Arch Opthalmol. 2001;119(8):1191-1199
45. Seddon JM. “Progression of age-related macular degeneration: association with dietary fat, transunsaturated fat, nuts, and fish intake.” Arch Ophthalmol. 2003 Dec;121(12):1728-37